PhytoHealth, Corporation

PhytoHealth Corporation announced a new clinical study results published at 2024 ESMO Congress: PG2 plus preoperative chemoradiotherapy improves survival in patients with locally advanced esophageal cancer

Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk

PhytoHealth Corporation Europe Taiwan

Cision View original content:https://www.prnewswire.co.uk/news-releases/phytohealth-corporation-announced-a-new-clinical-study-results-published-at-2024-esmo-congress-pg2-plus-preoperative-chemoradiotherapy-improves-survival-in-patients-with-locally-advanced-esophageal-cancer-302244040.html

en | CA00765C1086 | PHYTOHEALTH | boerse | 67925454 |